Shortwave Life Sciences (AQSE:PSY) Capex-to-Revenue : 0.00 (As of . 20)

View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Shortwave Life Sciences's Capital Expenditure for the six months ended in . 20 was £0.00 Mil. Its Revenue for the six months ended in . 20 was £0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Shortwave Life Sciences Capex-to-Revenue Historical Data

The historical data trend for Shortwave Life Sciences's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Capex-to-Revenue Chart

Shortwave Life Sciences Annual Data

Trend

Capex-to-Revenue

Shortwave Life Sciences Semi-Annual Data

Capex-to-Revenue

Competitive Comparison of Shortwave Life Sciences's Capex-to-Revenue

For the Biotechnology subindustry, Shortwave Life Sciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shortwave Life Sciences's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shortwave Life Sciences's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shortwave Life Sciences's Capex-to-Revenue falls into.

Shortwave Life Sciences Capex-to-Revenue Calculation

Shortwave Life Sciences's Capex-to-Revenue for the fiscal year that ended in . 20 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- ()	/
	=	N/A

Shortwave Life Sciences's Capex-to-Revenue for the quarter that ended in . 20 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- ()	/
	=	N/A

Shortwave Life Sciences (AQSE:PSY) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Shortwave Life Sciences Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shortwave Life Sciences's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shortwave Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.shortwavelifesciences.com

Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.